2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - R02-R05
Treatment Considerations, Combination Therapy, Drug Development, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

526 Updated results from the phase 3 sentry trial investigating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis

Pankit Vachhani, MD, Junshik Hong, MD2, Francesco Passamonti, MD3, Srinivas Tantravahi, MD4, Haris Ali, MD5, Raajit K. Rampal, MD, PhD6, Prithviraj Bose, MD7, John O. Mascarenhas, MD8, Tania Jain, MBBS9, Nikolai Podoltsev Podoltsev, MD, PhD10, Yair Levy, MD11, Krzysztof Giannopoulos, MD, PhD12, Sung-Eun Lee, MD, PhD13, Jean-Christophe Ianotto, MD, PhD, HDR14, Dominik Chraniuk, MD15, Daniela Cilloni, MD16, Martin Donchev, MD, PhD17, Raúl Pérez López, MD, PhD18, Claire Harrison, DM19, Haifa Kathrin Al-Ali, MD20, Yi Chai21, Pietro Taverna, PhD22, Tomer Mark, MD23, Darko Miljkovic, MSc/PhD24, Reshma Rangwala, MD, PhD25, Amama Sadiq, MD, MPH26, Alessandro Lucchesi, MD, PhD27
1 O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, United States
2 Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Rep. of South
3 Università degli Studi di Milano, Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca Granda, Milano, Italy
4 Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, United States
5 City of Hope Comprehensive Cancer Center, Duarte, California, United States
6 Memorial Sloan-Kettering Cancer Center, New York, New York, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 Tisch Cancer Institute, Icahn School of Medicine, New York, New York, United States
9 Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
10 Yale Cancer Center/Smilow Cancer Hospital, New Haven, Connecticut, United States
11 Texas Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
12 Medical University of Lublin, Lublin, Poland
13 Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Rep. of South
14 Service d'hématologie clinique, CHRU de Brest, Brest, France
15 Wojewódzki Szpital Zespolony w Toruniu, Torun, Poland
16 A.O. Ordine Mauriziano di Torino, Turin, Italy, University of Turin, Turin, Italy
17 Medical University Sofia, Sofia, Bulgaria, Specialized Hospital for Active Therapy of Hematological Diseases, Sofia, Bulgaria
18 University of Murcia, Murcia, Spain
19 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
20 Krukenberg Cancer Center Halle, University Hospital Halle (Saale), Halle, Germany
21 Karyopharm Therapeutics, Newton, Massachusetts, United States
22 Karyopharm Therapeutics, Newton, Massachusetts, United States
23 Karyopharm Therapeutics, Newton, Massachusetts, United States
24 Menarini Group, Zurich, Switzerland
25 Karyopharm Therapeutics, Newton, Massachusetts, United States
26 Karyopharm Therapeutics, Newton, Massachusetts, United States
27 U. O. Oncologia Medica, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy

Background: Myelofibrosis (MF) is a debilitating myeloproliferative neoplasm marked by splenomegaly, constitutional symptoms, and reduced survival. JAK inhibitors (JAKi), such as ruxolitinib (R), are standard frontline therapy. However, spleen volume reduction >35% (SVR35), symptom improvement, durable modification of underlying disease biology, and reduction of driver mutation variant allele frequency (VAF) are limited. In patients (pts) with JAKi–naïve MF, selinexor (S) plus R showed significantly improved SVR35 and comparable reduction in absolute total symptom score (AbsTSS) vs placebo plus R. An early, promising overall survival (OS) difference was observed favoring S+R in concert with improved biological markers (Bose P et al. J Clin Oncol. DOI: 10.1200/JCO-26-01080).

Aims: Follow-up efficacy, safety, and biologic markers of disease modification at Week (W) 48 from the Phase 3 SENTRY trial (NCT04562389).

Methods: Pts with JAKi-naïve MF were randomized 2:1 to S 60 mg weekly + R (per label) or placebo + R, stratified by Dynamic International Prognostic Scoring System (DIPSS) risk, spleen volume, and platelet count. Eligibility included spleen volume ≥450 cm³, active MF symptoms, DIPSS Intermediate-1 or higher, and platelets ≥100×10?/L. The coprimary endpoints were SVR35 and AbsTSS at W24. Secondary prespecified endpoints included safety and OS. Changes in driver mutation VAF, fibrosis grade, and plasma cytokines were exploratory. Levels of lactate dehydrogenase (LDH) and peripheral blood (PB) blasts were evaluated post hoc.

Results: Efficacy results are based on pts who reached W48 or discontinued prior to W48. The data cutoff is Feb 20, 2026, and data will be updated at the time of presentation.

353 pts were randomized (S+R, n=235; R, n=118). Baseline characteristics were balanced. As of data cut-off, median follow-up was 11.2 and 11.1 months in S+R and R, respectively. 36.8% (n=86/235) of S+R pts vs 35.3% (n=41/118) of R pts discontinued study treatment at any time. 74% (n=175/235) of S+R vs 70% (n=83/118) of R pts had either reached or discontinued treatment prior to W48, with SVR35 achieved in 36.6% vs 24.1% of pts treated with S+R vs R, respectively. Among those pts who had spleen assessments available, SVR35 at W48 was achieved in 64/84 (76.2%) with S+R vs 20/51 (39.2%) with R. The mean change in spleen volume at W48 was −47.0% vs −27.4%. The duration of response trended in favor of S+R vs R (HR=0.83; 95% CI 0.39, 1.80)

Mean (standard deviation) change from baseline in AbsTSS at W48 was −10.0 (10.8) with S + R (n=99) and −10.4 (10.9) with R (n=51).

A meta-regression of MF randomized clinical trials found SVR35 rates explained OS heterogeneity (r2~80%; P<0.05), supporting the previously presented association of SVR35 and OS observed in SENTRY.

Paired bone marrow biopsies (screening and W48) were available for 28 pts (S+R, n=18; R, n=10). At W48, 39% of S+R pts showed fibrosis grade improvement vs 30% of R, while 22% of S+R pts had worsened fibrosis grade vs 30% of R. Driver mutation VAF was evaluable at W48 for 83 S+R pts, and a decrease of ≥20% was reached in 34%.

Plasma cytokine levels were available for 329 pts (S+R, n=217; R, n=112); ≥50% reduction from baseline at W4, W24, or W48 of MF-related cytokines TNFα, IL-6, IL-4 and MIP-1B was observed in a higher % of S+R pts (44%, 42%, 73%, and 24%) compared with R (15%, 27%, 52%, and 5%).

Median LDH fell rapidly and durably with S+R (median -39.8% at W48) but was only minimally changed for R (-6.7% at W48). Likewise, emergence of PB blasts was more suppressed for S+R pts. Among pts with PB blasts at screening, 50% of S+R pts had completely cleared blasts by W48 compared with 38.5% of R. LDH and PB blasts were correlated with each other (W48: rho=0.56, P<0.001).

Updated W48 efficacy and safety results will be reported at the time of presentation.

Conclusion: These results demonstrate sustained clinical activity that continues to positively evolve through W48, further supporting the potential of XPO1+JAK inhibition as a therapeutic strategy in JAKi-naïve MF.

Pankit Vachhani, MD: Novartis - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Kartos - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Prelude Therapeutics - Consultancy (Includes expert testimony); DISC Medicine - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Merck & Co., Inc - Consultancy (Includes expert testimony)